Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
33
PURE Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
1.31%
Day range:
$0.05 - $0.05
52-week range:
$0.04 - $0.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.28x
P/B ratio:
--
Volume:
2.4K
Avg. volume:
59.9K
1-year change:
-22.64%
Market cap:
$5.4M
Revenue:
$2.2M
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, PURE Bioscience, Inc. has 6144.8% upside to fair value with a price target of -- per share.
PURE vs. S&P 500
-
Over the past 5 trading days, PURE Bioscience, Inc. has overperformed the S&P 500 by 3.93% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PURE Bioscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PURE Bioscience, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter PURE Bioscience, Inc. reported revenues of $708K.
Earnings Growth
-
PURE Bioscience, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter PURE Bioscience, Inc. reported earnings per share of -$0.00.
Enterprise value:
10.5M
EV / Invested capital:
80.48x
Price / LTM sales:
2.28x
EV / EBIT:
--
EV / Revenue:
4.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4M
Return On Assets:
-226.51%
Net Income Margin (TTM):
-92.35%
Return On Equity:
--
Return On Invested Capital:
-19070.18%
Operating Margin:
-53.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Income Statement | ||||||
| Revenue | $2.1M | $1.8M | $2.4M | $556K | $708K | |
| Gross Profit | $1.2M | $1M | $1.4M | $325K | $450K | |
| Operating Income | -$3.4M | -$3M | -$2M | -$627K | -$379K | |
| EBITDA | -$3.2M | -$2.9M | -$2M | -$627K | -$378K | |
| Diluted EPS | -$0.03 | -$0.03 | -$0.02 | -$0.01 | -$0.00 | |
| Period Ending | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5M | $3.1M | $2.1M | $911K | $1.2M | |
| Total Assets | $3.6M | $3.7M | $2.3M | $924K | $1.2M | |
| Current Liabilities | $828K | $699K | $806K | $911K | $3.2M | |
| Total Liabilities | $828K | $699K | $2.6M | $4.4M | $6.7M | |
| Total Equity | $2.7M | $3M | -$383K | -$3.5M | -$5.5M | |
| Total Debt | $239K | -- | $1.8M | $3.5M | $3.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.8M | -$2.6M | -$1.8M | -$503K | -$250K | |
| Cash From Investing | $4K | -- | -- | -- | -- | |
| Cash From Financing | $1.8M | $1.5M | $1.9M | $500K | $350K | |
| Free Cash Flow | -$2.8M | -$2.6M | -$1.8M | -$503K | -$250K | |
PURE
Sector
Market Cap
$5.4M
$118M
Price % of 52-Week High
22.49%
70.37%
Dividend Yield
0%
0%
Shareholder Yield
-6.97%
2.3%
1-Year Price Total Return
-22.64%
-7.26%
Beta (5-Year)
0.513
0.255
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.05
200-day SMA
Sell
Level
$0.07
Bollinger Bands (100)
Sell
Level
0.05 - 0.09
Chaikin Money Flow
Sell
Level
-302.7K
20-day SMA
Sell
Level
$0.05
Relative Strength Index (RSI14)
Sell
Level
45.09
ADX Line
Sell
Level
23.88
Williams %R
Neutral
Level
-76.5517
50-day SMA
Sell
Level
$0.06
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Sell
Level
-425.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-187.8292)
Sell
CA Score
(Annual)
Level (-32.2869)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (42.5176)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in El Cajon, CA.
Stock Forecast FAQ
In the current month, PURE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PURE average analyst price target in the past 3 months is --.
-
Where Will PURE Bioscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PURE Bioscience, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About PURE Bioscience, Inc.?
Analysts are divided on their view about PURE Bioscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PURE Bioscience, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is PURE Bioscience, Inc.'s Price Target?
The price target for PURE Bioscience, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PURE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PURE Bioscience, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PURE?
You can purchase shares of PURE Bioscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PURE Bioscience, Inc. shares.
-
What Is The PURE Bioscience, Inc. Share Price Today?
PURE Bioscience, Inc. was last trading at $0.05 per share. This represents the most recent stock quote for PURE Bioscience, Inc.. Yesterday, PURE Bioscience, Inc. closed at $0.05 per share.
-
How To Buy PURE Bioscience, Inc. Stock Online?
In order to purchase PURE Bioscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PURE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PURE
Sector
P/E ratio
--
16.71x
PEG ratio
--
0.13x
P/B ratio
--
1.48x
Price / LTM sales
2.28x
0.51x
Growth Metrics
PURE
Sector
Revenue growth
27.34%
2.99%
Earnings growth
32.26%
3.56%
Revenue (5-year growth)
-20.46%
3.31%
Earnings forecast
--
$0.32
Profitability
PURE
Sector
Profitability FY 2025
$1.3M
$263.1M
Return on invested capital
-19070.18%
4.37%
Return on assets
-226.51%
3.04%
Return on equity
--
7.48%
Earnings Date
Last Earnings Date
Jun
13
Next Earnings Date
Dec
31
Estimated Next Earnings Date
Apr
1
Balance Sheet
PURE
Sector
Total cash
$509K
$85.8M
Short term investments
--
$31.1M
Total assets
$1.1M
$1.1B
Long term debt
$3.6M
$6.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
